Cipla vs Lupin: Share Price, PE and ROE Compared
- August 13, 2026
- Posted by: Neeraj Pandey
- Category: Market
Cipla MCap approx Rs 1,00,000-1,15,000 Cr. Lupin MCap approx Rs 85,000-1,00,000 Cr. Both are India top-5 listed pharma companies with US and domestic businesses.
Quick Answer
Cipla and Lupin are two of India’s top five listed pharmaceutical companies. Both are large-caps with significant US generics and domestic branded formulations businesses. Cipla has historically had a strong branded India business; Lupin has a large US portfolio focused on complex generics and inhalers. Both trade at premium valuations reflecting pharma sector growth expectations.
The Cipla vs Lupin question comes up often among investors who follow the Large pharma companies space in India. Cipla MCap approx Rs 1,00,000-1,15,000 Cr. Lupin MCap approx Rs 85,000-1,00,000 Cr. This article goes through what each company does, their latest financial performance, and the key numbers that matter for anyone evaluating Cipla vs Lupin as a research exercise.
All data cited here is sourced from publicly available company filings. Note: Data is approximate. Verify the latest prices and fundamentals on NSE or BSE before acting on any information.
Cipla vs Lupin: Company Overview and Market Presence
Cipla operates in the Large pharma companies segment and is listed on Indian exchanges. Cipla MCap approx Rs 1,00,000-1,15,000 Cr The company has built its market position over the years through its core offerings to customers across India.
Click Here – Get Free Investment Predictions
Lupin is the other side of this Cipla vs Lupin comparison. Lupin MCap approx Rs 85,000-1,00,000 Cr It competes in the same Large pharma companies space, though its scale and strategy may differ significantly from Cipla’s approach.
When investors look at the Cipla vs Lupin pair, market capitalisation is usually the first filter. Cipla MCap approx Rs 1,00,000-1,15,000 Cr. Lupin MCap approx Rs 85,000-1,00,000 Cr. The size difference, if any, tells you something about liquidity and institutional ownership patterns.
Cipla vs Lupin: Business Mix and Revenue Sources
To understand the Cipla vs Lupin comparison fully, you need to look at how each company makes money. Cipla’s revenue comes from its core Large pharma companies operations. Cipla earns from the Large pharma companies segment.
Lupin similarly derives its earnings from the Large pharma companies space. Lupin operates in the Large pharma companies space. The product or service mix of the two companies can be similar or quite different depending on which subsegments each one serves.
Cipla vs Lupin: Financial Results and Key Ratios
This is where the Cipla vs Lupin comparison gets concrete. Return on equity, price-to-earnings ratio and market capitalisation are three metrics that help frame the relative position of each stock.
Cipla MCap approx Rs 1,00,000-1,15,000 Cr The profitability and efficiency ratios here reflect the latest available data from public filings.
Lupin MCap approx Rs 85,000-1,00,000 Cr Investors should note that Data is approximate.
Compare Cipla and Lupin on the Univest Screener
Cipla vs Lupin: Valuation and What the Market Is Pricing In
Valuation is a core part of any Cipla vs Lupin analysis. A high PE ratio can signal growth expectations or thin earnings. A low PE may indicate value or a business under stress. Neither is automatically good or bad without context.
Cipla MCap approx Rs 1,00,000-1,15,000 Cr. Lupin MCap approx Rs 85,000-1,00,000 Cr. Both are India top-5 listed pharma companies with US and domestic businesses. The Cipla vs Lupin stock data above reflects figures sourced from publicly available data. Prices change daily, so treat this as a starting point for your own research rather than a definitive trading signal.
Dividend yield is another data point worth checking in the Cipla vs Lupin pair. Some investors prioritise income alongside capital appreciation, and a consistent dividend track record can be a sign of earnings quality and management confidence in the cash flow.
Cipla vs Lupin: Side-by-Side Comparison
The table below captures the most relevant metrics side by side for the Cipla vs Lupin comparison.
| Parameter | Cipla | Lupin |
|---|---|---|
| MCap | approx Rs 1,00,000-1,15,000 Cr | approx Rs 85,000-1,00,000 Cr |
| Segment | Branded India + US generics | US generics + India branded |
| Data | Approximate | Approximate |
What Should Investors Know About the Cipla vs Lupin Choice
Every Cipla vs Lupin research exercise should go beyond just looking at the current share price. The sector outlook for Large pharma companies companies, the trajectory of earnings growth, debt levels and management quality all feed into a complete picture.
For the Cipla vs Lupin pair specifically: Cipla MCap approx Rs 1,00,000-1,15,000 Cr. Lupin MCap approx Rs 85,000-1,00,000 Cr. These numbers are a starting point. Investors should also look at the trend over four to eight quarters rather than just the latest standalone figure, since one strong quarter does not always reflect the underlying business quality.
If you are building a portfolio allocation decision around the Cipla vs Lupin comparison, consider the risk profile of your overall portfolio first. Both companies operate in Large pharma companies, which carries its own sector-specific risks including regulatory changes, commodity cost pressure, competitive intensity and macroeconomic sensitivity.
Conclusion
The Cipla vs Lupin comparison comes down to this: Cipla and Lupin are both listed Indian companies in the Large pharma companies space, but they differ in scale, valuation, and financial profile. Cipla MCap approx Rs 1,00,000-1,15,000 Cr. Lupin MCap approx Rs 85,000-1,00,000 Cr.
Cipla MCap approx Rs 1,00,000-1,15,000 Cr. Lupin MCap approx Rs 85,000-1,00,000 Cr. Both are India top-5 listed pharma companies with US and domestic businesses. Before taking any position in either stock, verify the latest fundamentals on NSE or BSE and consult a SEBI-registered investment advisor (registration number INH000013776).
Download the Univest iOS App or Univest Android App to track Cipla and Lupin live and get analyst-backed stock recommendations every day.
Disclaimer: Data and figures in this article are sourced from publicly available information and may not be fully accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice from Univest (SEBI RA INH000013776).
Frequently Asked Questions
What does Cipla do?
Ans. Cipla is a listed Indian company in the Large pharma companies segment. Visit univest.in for live data.
What does Lupin do?
Ans. Lupin is a listed Indian company in the Large pharma companies segment. Visit univest.in for live data.
Which is larger in the Cipla vs Lupin comparison?
Ans. Based on current data: Cipla MCap approx Rs 1,00,000-1,15,000 Cr. Verify from NSE or BSE.
How do PE ratios compare in Cipla vs Lupin?
Ans. The PE ratio comparison is in the data table above. Verify from NSE or BSE before investing.
What is the ROE of Cipla?
Ans. The ROE of Cipla is listed in the comparison table above. Verify from the latest quarterly filings.
Does Lupin pay dividends?
Ans. Dividend yield information for Lupin is in the comparison above. Verify from NSE or BSE.
How should I evaluate Large pharma companies stocks?
Ans. For Large pharma companies stocks, review earnings quality, ROE trends, debt levels and sector outlook. Consult a SEBI-registered advisor (INH000013776) before investing.
